Literature DB >> 29285506

Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not.

Thomas F Heston1,2, Anndres H Olson1, Nicholas R Randall1.   

Abstract

Entities:  

Year:  2017        PMID： 29285506      PMCID： PMC5733311          DOI： 10.21037/atm.2017.09.28

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

Review 1.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

2.  Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.

Authors:  Eric Berger
Journal:  Ann Emerg Med       Date:  2008-08       Impact factor: 5.721

3.  Sugar intake, serum insulin and platelet adhesiveness in men with and without peripheral vascular disease.

Authors:  J Yudkin; V V Kakkar; S Szanto
Journal:  Postgrad Med J       Date:  1969-09       Impact factor: 2.401

4.  Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.

Authors:  Julio Rosenstock; Leonard Chuck; Manuel González-Ortiz; Kate Merton; Jagriti Craig; George Capuano; Rong Qiu
Journal:  Diabetes Care       Date:  2016-01-19       Impact factor: 19.112

5.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

6.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Authors:  Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

Review 7.  Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Authors:  Norm Rosenthal; Gary Meininger; Kirk Ways; David Polidori; Mehul Desai; Rong Qiu; Maria Alba; Frank Vercruysse; Dainius Balis; Wayne Shaw; Robert Edwards; Scott Bull; Nicholas Di Prospero; Sue Sha; Paul Rothenberg; William Canovatchel; Keith Demarest
Journal:  Ann N Y Acad Sci       Date:  2015-08-25       Impact factor: 5.691

8.  Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.

Authors:  J P H Wilding; G Charpentier; P Hollander; G González-Gálvez; C Mathieu; F Vercruysse; K Usiskin; G Law; S Black; W Canovatchel; G Meininger
Journal:  Int J Clin Pract       Date:  2013-10-13       Impact factor: 2.503

Review 9.  Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews.

Authors:  Daniele Mandrioli; Cristin E Kearns; Lisa A Bero
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

10.  Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.

Authors:  Jessica Turner; Tahmina Begum; Roger D Smalligan
Journal:  J Investig Med High Impact Case Rep       Date:  2016-08-29
View more
  1 in total

Review 1.  Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure.

Authors:  Mieczysław Dutka; Rafał Bobiński; Izabela Ulman-Włodarz; Maciej Hajduga; Jan Bujok; Celina Pająk; Michał Ćwiertnia
Journal:  Heart Fail Rev       Date:  2020-11-04       Impact factor: 4.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.